Results 221 to 230 of about 215,808 (286)

Cefazolin population pharmacokinetics in children undergoing maintenance hemodialysis for kidney failure. [PDF]

Antimicrob Agents Chemother
Berthaud R, Urien S, Krid S, Foissac F, Oualha M, Thy M, Boyer O, Béranger A, Hirt D, Benaboud S, Tréluyer J-M, Bouazza N.   +11 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

American Journal of Hematology, EarlyView.
ABSTRACT Ravulizumab, a second‐generation complement component 5 inhibitor (C5i) derived from eculizumab, with improved pharmacokinetics, is the current standard‐of‐care treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), where available.
Alexander Röth, Christopher J. Patriquin, Jeff Szer, Louis Terriou, Ami S. Patel, Jesse Metzger, Philippe Gustovic, Jun‐ichi Nishimura, Robert A. Brodsky   +8 more
wiley   +1 more source

Population pharmacokinetics and dose optimization of piperacillin-tazobactam in premature and term neonates with severe infections. [PDF]

Antimicrob Agents Chemother
Boer-Pérez FS, Lima-Rogel V, Romano-Moreno S, Mejía-Elizondo AR, Medellín-Garibay SE, Schaiquevich P, Noyola-Cherpitel DE, Rodríguez-Báez AS, Rodríguez-Pinal CJ, Milán-Segovia RdC.   +9 more
europepmc   +1 more source

Metformin enhances external urethral sphincter integrity and restores continence via AMPK activation in a rat model of stress urinary incontinence

Animal Models and Experimental Medicine, EarlyView.
The pathogenesis of stress urinary incontinence (SUI) is intimately associated with injury to the external urethral sphincter (EUS). In this study, we established an SUI model induced by double vaginal distension and demonstrated that metformin treatment activated the AMPK signaling in the EUS tissue.
Yuting Xu, Xuhong Li, Alvaro Munoz, Li Jiang, Lihua Huang, Yanhua Zhou, Liping Zhu, Youbo Yang   +7 more
wiley   +1 more source

Population Pharmacokinetics and Covariate Analysis of Methotrexate in Pediatric Acute Lymphoblastic Leukemia. [PDF]

Drug Des Devel Ther
Yu B, Wan Y, Mei K, Zhan D, Tang Q, Hu X, Ji W, Cai H.   +7 more
europepmc   +1 more source

Advances and Challenges in Micro/Nanocarrier‐Based Dermal Drug Delivery Systems for Acne Treatment

Advanced NanoBiomed Research, EarlyView.
Topical acne treatment faces challenges from skin barriers and complex causes. Micro/nanocarriers improve drug delivery by enhancing bioavailability, targeting, and duration. Combining carriers creates synergistic effects for systematic intervention.
Jintao Yang, Jie Chen, Yunmiao Ma, Qingwei Zhou, Yu Kong, Yingxiang Chen, Junjie Chi, Haihua Hu   +7 more
wiley   +1 more source

Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposure. [PDF]

PLoS One
Jayanti RP, Cho YS, Soedarsono S, Kim HJ, Kang J, Kim J, Oh JY, Kang BH, Ha JH, Kim JW, Mertaniasih NM, Kusmiati T, Permatasari A, Yuliwulandari R, Kim R, Seong HJ, Ghim JL, Kim DH, Shin JG, cPMTb.   +19 more
europepmc   +1 more source

Beyond PEGylation: Archaeal Lipids for Long‐Circulating Liposomes

Advanced NanoBiomed Research, EarlyView.
Archaeal lipid‐based liposomes, particularly those containing caldarchaeol (GDGT), were found to significantly prolong the circulation time of vancomycin in rats, matching the pharmacokinetic properties of PEGylated systems. These findings suggest archaeal lipids as promising non‐PEG excipients for parenteral applications to minimize drug clearance ...
Viktor Sedlmayr, Andreas D. Meid, Eric Mühlberg, Manuel Ben Böhmann, Julian Quehenberger, David Wurm, Mikko Gynther, Oliver Spadiut, Gert Fricker, Philipp Uhl   +9 more
wiley   +1 more source

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV. [PDF]

Antimicrob Agents Chemother
Tsirizani L, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, Chitsamatanga M, Rutebarika DA, Musiime V, Kasozi M, Lugemwa A, McIlleron HM, Burger DM, Gibb DM, Colbers A, Denti P, Wasmann RE, CHAPAS-4 trial team.   +17 more
europepmc   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source